Organon (OGN) Change in Intangibles (2021 - 2025)
Organon (OGN) recorded quarterly Change in Intangibles of $69.0 million in Q3 2025, up 25.45% quarter-over-quarter from $55.0 million in Q1 2025, and up 200.0% on a YoY basis from $23.0 million in Q3 2024.
Organon (OGN) Change in Intangibles (2021 - 2025) Analysis & Trends
Organon's Change in Intangibles history runs 5 years deep, the most recent figure standing at $69.0 million for Q3 2025.
- In Q3 2025, Change in Intangibles rose 200.0% year-over-year to $69.0 million; the TTM figure through Mar 2026 stood at $69.0 million (down 37.27% YoY), while the FY2025 annual figure was $124.0 million, up 18.1% from the prior year.
- Change in Intangibles was $69.0 million for Q3 2025 at Organon, up from $55.0 million in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of $192.0 million in Q2 2021 to a low of $2.0 million in Q4 2023.
- Historically, Change in Intangibles has averaged $51.0 million across 5 years, with a median of $35.5 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Change in Intangibles tumbled 79.69% in 2022, then jumped 1500.0% in 2024.
- A 5-year view of Change in Intangibles shows it stood at $192.0 million in 2021, then tumbled by 90.62% to $18.0 million in 2022, then sank by 88.89% to $2.0 million in 2023, then surged by 1500.0% to $32.0 million in 2024, then jumped by 115.62% to $69.0 million in 2025.
- The last three Change in Intangibles figures came in at $69.0 million (Q3 2025), $55.0 million (Q1 2025), and $32.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | -299.30 Mn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | - |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | - |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | - |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | - |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 69.00 Mn |
| Sep 30, 2025 | 69.00 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Dec 31, 2024 | 32.00 Mn |
| Dec 31, 2024 | 32.00 Mn |
| Sep 30, 2024 | 23.00 Mn |
| Sep 30, 2024 | 23.00 Mn |
| Mar 31, 2024 | 50.00 Mn |
| Mar 31, 2024 | 50.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2022 | 18.00 Mn |
| Sep 30, 2022 | 18.00 Mn |
| Jun 30, 2022 | 39.00 Mn |
| Jun 30, 2022 | 39.00 Mn |
| Mar 31, 2022 | 30.00 Mn |
| Mar 31, 2022 | 30.00 Mn |
| Jun 30, 2021 | 192.00 Mn |
| Jun 30, 2021 | 192.00 Mn |